Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
NCT ID: NCT00704795
Last Updated: 2008-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
20 participants
OBSERVATIONAL
2008-06-30
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients with type 1 diabetes mellitus
Oral glucose tolerance test
50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
Isoglycemic iv glucose infusion
The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
2
Healthy control subjects matched for body mass index (BMI), age and gender.
Oral glucose tolerance test
50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
Isoglycemic iv glucose infusion
The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral glucose tolerance test
50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
Isoglycemic iv glucose infusion
The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No residual beta-cell function (arginine test without increment in plasma C-peptide - see below)
* BMI \<30 kg/m2
* Normal haemoglobin
* Informed consent
Exclusion Criteria
* Known liver disease or affected liver enzymes (ALAT/ASAT \> 2 x upper normal limit)
* Diabetic nephropathy (se-creatinin \> 130 µM and/or albuminuria)
* Proliferative diabetic retinopathy (anamnestic)
* Treatment with medication that cannot be discontinued for 14 hours
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gentofte University Hospital, Copenhagen
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Filip K Knop, MD PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Gentofte, Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gentofte University Hospital
Hellerup, Hellerup, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-D-2008-037
Identifier Type: -
Identifier Source: org_study_id